Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05619510 · ClinicalTrials.gov registry record · NA

Pain Reduction Through Empowered Recovery (PRIME) Study

A NA study of Depression and Depressive Symptoms, sponsored by Johns Hopkins University.

Active
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT05619510: Active NA study of Depression and Depressive Symptoms, sponsored by Johns Hopkins University.

NCT05619510 is a NA study of Depression and Depressive Symptoms that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05619510, a NA study of Depression and Depressive Symptoms, is active but no longer recruiting, sponsored by Johns Hopkins University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Chronic pain and depression or low mood are often experience by women who age with or into disabilities. Due to various factors women with disabilities often experience this cycle of pain and depression. Both of these conditions can be debilitating and lead to declines in health. Treating these conditions simultaneously, particularly , in older adults can be complicated due to side effects, risks of poor access to pain management and mental health care , and complications from other co occuring conditions. In order to address this cycle in older women with disabilities the investigators are testing the Women in Pain Reduction through Improved Mood and Empowerment (PRIME) study. The PRIME intervention includes four in person visits by a nurse to the women's homes where the participants set goals regarding pain and depression and the nurse helps the participants strategize ways to meet these goals. The second component of the study will be eight group sessions virtually with other participants in the study. The group sessions will be led by a clinical psychologist who will engage in Acceptance Commitment Therapy with the women.

Primary Outcome

Pain Intensity was measured by the Patient-Reported Outcomes Measurement Information System . Pain intensity measure. Patient-Reported Outcomes Measurement Information System . Survey uses a standardized T-score metric based on a mean of 50 and a standard deviation of 10. Higher score worse pain.

Interventions

  • BEHAVIORAL PRIME Intervention

Study Locations (1)

Maryland

  • Johns Hopkins School of Nursing - Baltimore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-03-31
Est. Completion 2026-05-31
Phase NA
Johns Hopkins University

1,448 total trials

What the registry record for NCT05619510 still lists

NCT05619510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).

The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which PRIME Intervention is the first listed.

NCT05619510 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT05619510 about?

NCT05619510 is a clinical study titled "Pain Reduction Through Empowered Recovery (PRIME) Study". Chronic pain and depression or low mood are often experience by women who age with or into disabilities. Due to various factors women with disabilities often experience this cycle of pain and depression. Both of these conditions can be debilitating and lead to declines in health. Treating these cond...

What is the current status of trial NCT05619510?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-03-31. Estimated completion is 2026-05-31.

What conditions does trial NCT05619510 study?

This clinical trial studies the following conditions: Depression, Depressive Symptoms, Pain, Chronic, Disability Physical.

What interventions are being tested in trial NCT05619510?

The interventions under investigation include: PRIME Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05619510?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05619510 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05619510's enrollment target sits among peer trials

30 557th of 679 higher than 105 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05619510, the US trial registry maintained by the National Library of Medicine. NCT05619510 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.